Barclays analyst Saket Kalia maintains Definitive Healthcare (NASDAQ:DH) with a Equal-Weight and raises the price target fro...

Definitive Healthcare's Q4 2023 performance, with adjusted EPS at $0.07, sales of $65.93 million, and a 5% Y/Y growth in en...

Canaccord Genuity analyst David Hayes maintains Definitive Healthcare (NASDAQ:DH) with a Hold and raises the price target fr...

Full Year 2024:  Revenue is expected to be in the range of $263.0 – $269.0 million, a 5-7% increase from the prior year at the ...

Business Outlook Based on information as of February 28, 2024, the Company is issuing the following financial guidance. This gu...

Definitive Healthcare (NASDAQ:DH) reported quarterly earnings of $0.07 per share which missed the analyst consensus estimate of...

Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenu...